Condition: Chronic Obstructive Pulmonary Disease (COPD) · Sponsor: Expedition Therapeutics, Inc
This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study drug or placebo administered once daily for 52 weeks.
This description comes directly from the study's public registry record.
Geoffrey Gilmartin, MD · 617-775-9882 · geoff.gilmartin@expeditiontx.com
Always discuss trial participation with your own doctor first.
| DM Clinical Research - Phoenix | Phoenix, Arizona, United States | Recruiting |
| California Medical Research Associates Inc. | Northridge, California, United States | Recruiting |
| Lynn Institute of Denver | Aurora, Colorado, United States | Recruiting |
| Clinical Site Partners, LLC Leesburg dba Flourish Research | Leesburg, Florida, United States | Recruiting |
| Suncoast Research Group, LLC Miami - Little Havana dba Flourish Research | Miami, Florida, United States | Recruiting |
| Optimal Research Sites | Orange, Florida, United States | Recruiting |
| Centricity Research Columbus | Rincon, Georgia, United States | Not Yet Recruiting |
| DM Clinical Research-Indianapolis | Indianapolis, Indiana, United States | Recruiting |
| Cotton O'Neil Clinical Research Center | Topeka, Kansas, United States | Recruiting |
| DM Clinical Research - Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| DM Clinical Research- Tomball | Tomball, Texas, United States | Recruiting |
| Burke Internal Medicine, Inc. | Burke, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07684820